Volume 224 - Published ahead of Issue 11

Influenza A(H3N2) Subclade K Activity in Australia in 2025: Epidemiology and Vaccine Effectiveness Results From General Practice Sentinel Surveillance

Authors:  Monique B. N. Chilver, Sheena G. Sullivan, Caitlin A. Selway, Jessica E. Miller, Nigel P. Stocks

Correspondence: monique.chilver@adelaide.edu.au

Med J Aust 2026 || doi: 10.5694/mja2.70336
Published online: 18 November 2026

Abstract

Objectives 

To describe the epidemiology, clinical characteristics, vaccine effectiveness (VE), antiviral prescribing and virological properties for influenza A(H3N2) subclade K detected through Australian general practice sentinel surveillance in 2025.

Study Type

Retrospective, observational study using routinely collected general practice surveillance data; VE was estimated using a test-negative design.

Setting, Patients

Data were collected from sentinel general practice sites participating in Australian Sentinel Practices Research Network surveillance across Australia during International Organization for Standardization weeks 1–52 of 2025. Patients presenting with influenza-like illness were systematically selected for virological sampling.

Main Outcome Measures

Demographic and clinical characteristics of patients with laboratory-confirmed influenza; VE against general practice-attended, laboratory-confirmed influenza; antiviral prescribing; and sequence-based markers of reduced antiviral susceptibility.

Results

Among 3185 patients with influenza-like illness who were swabbed, 666 (21%) tested positive for influenza. Influenza A(H3N2) subclade K was first detected in week 34 of 2025 and circulated beyond the typical influenza season, peaking in November–December. Of 98 subclade K detections, 36 (37%) were in children aged 5–17 years. Compared with other types, subtypes or subclades of influenza, clinical presentations of subclade K cases were broadly similar, with no consistent clinical pattern distinguishing subclade K. VE against subclade K was 50% overall (95% confidence interval, 8.9–73) and 76% among persons aged 9 months to 17 years (95% confidence interval, 18–93). Among all patients with a recorded antiviral prescription, two-thirds were within the recommended 48-h symptom onset window (76/114). No subclade K viruses had mutations known to reduce susceptibility to the influenza antivirals assessed, including oseltamivir.

Conclusion

Among patients attending Australian sentinel general practices in 2025, subclade K prolonged influenza activity into the summer months. General practice sentinel surveillance of influenza can provide timely information on emerging variants and changes in the timing of influenza circulation, raising clinical awareness outside the usual season, informing vaccination strategies and prompting assessment for antiviral treatment.


More like this